10-K: Senti Biosciences Faces Going Concern Doubt Amidst Clinical Progress

Senti Biosciences reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite positive Phase 1 clinical data for its lead CAR-NK cell therapy, SENTI-202.

Summary

• Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its gene circuit platform technologies for incurable diseases.
• The company reported a net loss of $61.4 million for the year ended December 31, 2025, an increase from $52.8 million in 2024.
• As of December 31, 2025, cash and cash equivalents stood at $16.4 million, down from $48.3 million in 2024, with an accumulated deficit of $358.6 million.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern beyond the second quarter of 2026 without additional financing.
• SENTI-202, the lead product candidate for relapsed/refractory hematological malignancies including AML, showed a 50% overall response rate and 42% CR/CRh in Phase 1 trials, with a 7.6 months median duration of composite Complete Remission.
• SENTI-202 received Orphan Drug Designation on June 18, 2025, and Regenerative Medicine Advanced Therapy (RMAT) designation on December 9, 2025, from the FDA.
• The collaboration with Celest Therapeutics for SN301A in China was terminated in April 2025 due to observed dose-limiting toxicities.
• Senti Biosciences entered into an At-The-Market (ATM) offering program in March 2025, selling 4,833,477 shares for net proceeds of $10.6 million.
• The company resolved a default on its Alameda facility lease and amended its sublease with GeneFab in March 2026, reducing leased space and converting past-due rent into manufacturing credits.
• A material weakness in internal control over financial reporting related to insufficient finance and accounting resources, identified in 2024, was remediated in 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging financial situation, with significant going concern risk and increasing losses, despite some positive clinical progress for its lead candidate. The termination of a partnered clinical trial adds to the negative sentiment.

Positives

• SENTI-202, the lead product candidate, demonstrated a 50% overall response rate and 42% complete remission (CR/CRh) in Phase 1 clinical trials for relapsed/refractory hematological malignancies, including AML.
• 100% of CRs and 83% of all responses for SENTI-202 were assessed as measurable residual disease (MRD) negative at the recommended phase 2 dose (RP2D), with a 7.6 months median duration of composite Complete Remission.
• SENTI-202 showed a favorable safety profile in all treated patients.
• The FDA granted Orphan Drug Designation to SENTI-202 for relapsed/refractory hematological malignancies including acute myeloid leukemia on June 18, 2025.
• The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 on December 9, 2025, based on Phase 1 clinical data.
• The company successfully remediated a previously identified material weakness in its internal control over financial reporting in 2025.
• Secured $8.0 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to support SENTI-202 clinical development.

Negatives

• The company incurred a net loss of $61.4 million for the year ended December 31, 2025, an increase from $52.8 million in 2024.
• Cash and cash equivalents decreased significantly to $16.4 million as of December 31, 2025, from $48.3 million in 2024.
• The accumulated deficit grew to $358.6 million as of December 31, 2025.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern beyond the second quarter of 2026 without additional financing.
• The collaboration with Celest Therapeutics for SN301A in China was terminated in April 2025 due to observed dose-limiting toxicities in the clinical trial.
• The company undertook a workforce reduction of approximately 37% in January 2024 to streamline business operations, incurring one-time severance and related costs.
• GeneFab, a related party and key manufacturing partner, was in default under its sublease agreements as of December 31, 2025, and had overdue rent payments, negatively impacting the company's cash flow and operations.
• The company's ability to collect all amounts owing from GeneFab in cash has negatively impacted its ability to continue as a going concern.

Risks

• The company is an early-stage clinical biotechnology company with a history of losses and expects to continue incurring significant losses, potentially never achieving profitability.
• Substantial doubt exists about the company's ability to continue as a going concern, requiring significant additional funding which may not be available on acceptable terms or at all.
• Failure to raise additional capital could force the company to restructure, delay, reduce, or terminate research and development programs or commercialization efforts.
• The company's current product candidates are in early clinical or preclinical development and may fail in clinical development or suffer delays, materially affecting their ability to receive regulatory approval or attain commercial viability.
• Gene circuit platform technologies are novel and unproven, potentially not resulting in approvable or marketable products, leading to unforeseen risks and difficulty in predicting development time and cost.
• Serious complications or side effects from product candidates in clinical trials or post-approval could lead to discontinuation of development, refusal of regulatory approval, or revocation of marketing authorizations.
• Projected discovery and development milestones may not be achieved in anticipated timeframes, impacting payments from collaboration agreements and stock price.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Reliance on third parties, particularly GeneFab, for manufacturing and clinical trials poses risks of unsatisfactory performance, supply limitations, interruptions, or quality issues.
• The company faces intense competition from larger, better-funded pharmaceutical and biotechnology companies developing similar or superior product candidates and technologies.
• Significant risk of product liability exists, and insufficient insurance coverage could materially harm the business.
• Adverse global economic conditions, including inflation, capital market disruptions, geopolitical events, and changes in government policies, could negatively impact business operations and financial condition.
• Cybersecurity breaches, security incidents, or unauthorized access to data could lead to significant costs, liabilities, business disruption, and reputational harm.
• Inability to obtain or protect intellectual property rights, or challenges to existing rights, could allow competitors to commercialize similar products and harm the company's competitive position.
• Changes in U.S. patent law or the patent law of other countries could diminish the value of patents and impair the ability to protect technologies.
• The company may be subject to lawsuits alleging infringement of third-party intellectual property rights, leading to substantial costs, liability, and potential inability to commercialize products.
• Failure to protect trade secrets could harm the business and competitive position.
• The company may be subject to claims of wrongful use or disclosure of third-party trade secrets or proprietary information by employees or consultants.
• Obtaining and maintaining patent protection depends on compliance with various procedural and fee payment requirements, and non-compliance could lead to loss of patent rights.
• If trademarks and trade names are not adequately protected, the company may not be able to build name recognition and its business may be adversely affected.
• Clinical development is a lengthy and expensive process with uncertain outcomes, and earlier study results may not predict future trial results.
• Inability to obtain U.S. or foreign regulatory approval would prevent commercialization of product candidates.
• Ongoing regulatory obligations and review post-approval may result in significant additional expense, labeling restrictions, or market withdrawal.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies could harm the business even if products are approved.
• Non-compliance with U.S. and foreign anti-corruption and anti-money laundering laws could lead to criminal or civil liability.
• Disruptions at the FDA and other government agencies due to funding shortages or policy changes could delay product development and approval.
• Natural disasters, public health crises, political unrest, or other catastrophic events could adversely affect business operations and supply chain.
• Quarterly operating results may fluctuate significantly, potentially falling below investor or analyst expectations, causing stock price volatility.
• The company may be subject to claims challenging the inventorship of its patents and other intellectual property.
• The company's executive officers, directors, principal stockholders, and their affiliates exercise significant influence, limiting other stockholders' ability to influence corporate matters or changes in control.
• The company has issued a substantial number of warrants exercisable into common stock, which could result in significant dilution to existing stockholders.

Future Outlook

Senti Biosciences plans to advance its internal pipeline of CAR-NK cell therapies for blood cancer indications through the clinical development of SENTI-202 and develop additional solid tumor cell therapy programs. The company intends to leverage partnering for non-oncology programs and manufacturing, and establish additional collaborations for other modalities. Substantial additional funding is necessary to maintain current operations and continue research and development activities, with management actively pursuing further financing.

Management Comments

• Management has concluded that there is substantial doubt as to whether the company can continue as a going concern for 12 months following the filing of this Annual Report and that without additional financing, operations may not continue past the second quarter of 2026.
• Management is devoting substantially all efforts to developing the company's business, raising capital, and collecting amounts owed under existing agreements.

Industry Context

StockSavvy.ai notes that Senti Biosciences operates in the highly competitive and capital-intensive cell and gene therapy landscape, particularly in oncology. The company's focus on CAR-NK cell therapies with gene circuit technologies represents a novel approach to address challenges like tumor heterogeneity and on-target/off-tumor toxicity, which are significant hurdles in the broader industry. While the industry has seen successes in CAR T-cell therapies for B-cell malignancies, AML remains an area of high unmet need, making SENTI-202's progress noteworthy. However, the termination of the Celest Therapeutics collaboration highlights the inherent risks and complexities of developing and commercializing novel therapies, especially in international markets. The company faces competition from numerous established pharmaceutical and biotechnology firms with greater resources, underscoring the need for strong clinical data and strategic partnerships.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• GeneFab, LLC (a wholly-owned subsidiary of Valere Bio, Inc., which is wholly owned by Celadon Partners, LLC) is a related party. Transactions include sublease agreements for the Alameda facility and a portion of the HQ lease, a development and manufacturing services agreement (DMSA), and a letter agreement for back rent payment and prepayment credits.
• Celadon Partners, LLC (Celadon) held 31.7% of outstanding common stock as of December 31, 2025, and is the parent company of GeneFab. Celadon was assigned the GeneFab Option and designated two directors to the Board.
• New Enterprise Associates, Inc. (NEA) held 12.2% of outstanding common stock as of December 31, 2025, and held one of the eight seats on the Board.
• Bayer Healthcare LLC (Bayer) held 19.9% of outstanding common stock as of December 31, 2025, and is the parent company of BlueRock Therapeutics LP.
• BlueRock Therapeutics LP (BlueRock) is a related party with whom the company has a collaboration and option agreement for the development of certain therapy products. The company recognized $22 thousand in collaboration revenue from BlueRock in 2025.
• Donald Tang, a manager of Celadon Partners, was appointed to the Board of Directors in December 2024.

Stakeholder Impact

• **Shareholders:** Face significant dilution from recent and potential future capital raises, including the ATM program and private placement. The substantial doubt about going concern and increased net losses pose a high risk to investment value. The stock price is volatile and has declined significantly from initial offering prices.
• **Employees:** Experienced a 37% workforce reduction in January 2024. The company's ability to attract and retain qualified personnel is critical but challenged by financial instability and competition.
• **Customers/Patients:** SENTI-202's positive Phase 1 data and FDA designations (Orphan, RMAT) offer hope for patients with relapsed/refractory hematological malignancies, including AML, addressing a high unmet medical need. However, the early stage of development and financial risks mean commercial availability is uncertain.
• **Suppliers/Creditors:** The company's reliance on third-party manufacturers (GeneFab) and the past default on sublease payments highlight risks for suppliers and creditors. The resolution of the GeneFab default through manufacturing credits indicates a complex financial relationship.
• **Regulatory Authorities:** The company is subject to extensive and evolving U.S. and foreign regulations, with ongoing scrutiny of clinical trials, manufacturing, and data privacy. Compliance failures could lead to significant penalties and delays.

Next Steps

• Advance internal pipeline of CAR-NK cell therapies for blood cancer indications through the clinical development of SENTI-202.
• Advance the development of additional solid tumor cell therapy programs utilizing gene circuit technologies.
• Leverage partnering to support indications beyond oncology, including the ongoing partnership with BlueRock Therapeutics.
• Establish additional value-creating collaborations to access the full potential of the technology in other modalities (T cells, TILs, stem cells, in vivo gene therapy, mRNA).
• Actively pursue additional financing to maintain current operations and continue research and development activities.
• Monitor GeneFab's payment status and collectibility of sublease payments, and other relevant factors affecting asset recoverability.

Key Dates

Recommendation

Despite promising early clinical data for SENTI-202 and key FDA designations, the company's severe financial distress, including substantial doubt about its ability to continue as a going concern, increasing net losses, and significant cash burn, presents an extremely high investment risk. The need for substantial additional financing, coupled with past partnership setbacks and dilution from recent capital raises, indicates a precarious financial position that outweighs the clinical progress for a seasoned investor.

Keywords

Senti Biosciences, SNTI, Biotechnology, Clinical-stage, Gene therapy, Cell therapy, Gene circuit platform, CAR-NK, Natural Killer cells, Oncology, Hematological malignancies, Acute Myeloid Leukemia, AML, SENTI-202, Orphan Drug Designation, RMAT designation, FDA, Synthetic biology, Logic Gating, NOT Gate, OR Gate, CD33, FLT3, Endomucin, EMCN, crIL15, Preclinical development, Clinical trials, Manufacturing, GeneFab, Celest Therapeutics, BlueRock Therapeutics, Intellectual property, Going concern, Financial results, Nasdaq